Cargando…

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts

AIM: ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine – composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors. METHODS: In this double-blinded, randomized, Phase II study bevacizumab-naive patients with recurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bota, Daniela A, Chung, Jinah, Dandekar, Manisha, Carrillo, Jose A, Kong, Xiao-Tang, Fu, Beverly D, Hsu, Frank PK, Schönthal, Axel H, Hofman, Florence M, Chen, Thomas C, Zidovetzki, Raphael, Pretto, Chrystel, Strik, Ankie, Schijns, Virgil EJC, Stathopoulos, Apostolos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200061/
https://www.ncbi.nlm.nih.gov/pubmed/30157683
http://dx.doi.org/10.2217/cns-2018-0009